Title :

Overview of � druggable � alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies

Author(s) :

Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Lebellec, Loic [Auteur]
Blay, Jean-Yves [Auteur]
Robin, Yves-Marie [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Journal title :

Critical Reviews in Oncology/Hematology

Abbreviated title :

Crit. Rev. Oncol. Hematol.

Volume number :

150

Pages :

102960

Publication date :

2020-04-14

ISSN :

1879-0461

Keyword(s) :

Druggable alterations
Personalized treatment
Sarcomas
Molecular targeted therapies

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

We summarize herein the literature data about molecular targeted therapies in sarcomas and conjunctive tissue intermediate malignancies. For each clinical setting, the level of evidence, the mechanism of action and the ...
Show more >We summarize herein the literature data about molecular targeted therapies in sarcomas and conjunctive tissue intermediate malignancies. For each clinical setting, the level of evidence, the mechanism of action and the target are described. The two major axes include (i) identification of subgroups of tumors with druggable alteration irrespective of the histological diagnosis (e.g. NTRK), and (ii) druggable target of pathway related to the physiopathology of the tumor: denosumab and bone giant cell tumor, imatinib and soft tissue giant cell tumor, mTOR inhibitor and PECOMA.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
INSERM
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
• Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Submission date :

2022-06-15T13:59:31Z